Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study

NCT02100618 · clinicaltrials.gov ↗
PHASE3
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped Due to late study start, the possibility to enroll enough subjects dropped below the limit to provide scientifically acceptable data, hence study was cancelled.

Conditions

Interventions

Sponsor

GlaxoSmithKline